SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

NAUMANN-ETIENNE RUEDIGER

(Last)

(First)

(Middle)

3304 MONTE VILLA PARKWAY

(Street)

BOTHELL

98021

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
QUINTON CARDIOLOGY SYSTEMS INC [ QUIN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		Former Director and Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2005

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/01/2005		D		124,054	D	⁽¹⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.2	09/01/2005		D			186,818	⁽²⁾	08/14/2010	Common Stock	186,818	⁽²⁾	0	D
Stock Option (Right to Buy)	$2.2	09/01/2005		D			204,545	⁽³⁾	12/01/2010	Common Stock	204,545	⁽³⁾	0	D
Stock Option (Right to Buy)	$8.37	09/01/2005		D			40,000	⁽⁴⁾	06/27/2012	Common Stock	40,000	⁽⁴⁾	0	D
Stock Option (Right to Buy)	$6	09/01/2005		D			30,000	⁽⁵⁾	02/10/2013	Common Stock	30,000	⁽⁵⁾	0	D
Stock Option (Right to Buy)	$9.32	09/01/2005		D			45,000	⁽⁶⁾	02/11/2014	Common Stock	45,000	⁽⁶⁾	0	D

Explanation of Responses:

1. Disposed of pursuant to Agreement and Plan of Merger between the Company and Cardiac Science Corporation in exchange for 95,750 shares of Cardiac Science Corporation common stock having a market value of $11.75 per share on the effective date of the merger.

2. This option was assumed by Cardiac Science Corporation in the merger and replaced with an option to purchase 144,195 shares of Cardiac Science Corporation for $2.85 per share.

3. This option was assumed by Cardiac Science Corporation in the merger and replaced with an option to purchase 157,878 shares of Cardiac Science Corporation for $2.85 per share.

4. This option was assumed by Cardiac Science Corporation in the merger and replaced with an option to purchase 30,874 shares of Cardiac Science Corporation for $10.84 per share.

5. This option was assumed by Cardiac Science Corporation in the merger and replaced with an option to purchase 23,155 shares of Cardiac Science Corporation for $7.77 per share.

6. This option was assumed by Cardiac Science Corporation in the merger and replaced with an option to purchase 34,733 shares of Cardiac Science Corporation for $12.07 per share.

	By: Timothy J. Way, Attorney-in-Fact	09/06/2005
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.